Evidence map›Paper›PMID 40593478›Full record

ArticleNature communications2025

Ligand-controlled regiodivergent and enantioselective hydrophosphorylation of styrenes by palladium.

Chun Ma, Xinyue Wang, Tibor Soós, Junliang Zhang, Junfeng Yang

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chun MaDepartment of Chemistry, Fudan University, 2005 Songhu Road, Shanghai, 200438, China.
Xinyue WangDepartment of Chemistry, Fudan University, 2005 Songhu Road, Shanghai, 200438, China.
Tibor SoósInstitute of Organic Chemistry, Research Centre for Natural Sciences, Magyar tudósok körútja 2, H-1117 5, Budapest, Hungary.ORCID http://orcid.org/0000-0002-2872-4313
Junliang ZhangDepartment of Chemistry, Fudan University, 2005 Songhu Road, Shanghai, 200438, China. junliangzhang@fudan.edu.cn.ORCID http://orcid.org/0000-0002-4636-2846
Junfeng YangDepartment of Chemistry, Fudan University, 2005 Songhu Road, Shanghai, 200438, China. yangjf@fudan.edu.cn.ORCID http://orcid.org/0000-0001-5209-1301

Funding

National Natural Science Foundation of China (National Science Foundation of China) 22031004National Natural Science Foundation of China (National Science Foundation of China) 22471040Shanghai Municipal Education Commission 20212308
6 · The paper itself

Abstract

Asymmetric hydrophosphorylation of unsaturated compounds is a straightforward and atom-economic approach to obtain chiral organophosphorus compounds. Herein, we describe a ligand-controlled regiodivergent and enantioselective hydrophosphorylation of styrenes facilitated by Pd catalysis and a PC-Phos ligand. This methodology enables the facile synthesis of both Markovnikov and anti-Markovnikov alkyl phosphorus compounds with high to excellent regio- and enantioselectivity, achieving up to >95:5 rr and 92% ee. Deuterium-labeling experiment and computational mechanistic studies unveil that the migratory insertion is the enatio-determining step, in which the O···H hydrogen bonding between the H-phosphonate and the ligand is identified as a crucial factor. Furthermore, our investigations demonstrate that both migratory insertion and reductive elimination contribute to achieving high regioselectivity and enantioselectivity. These findings not only advance the field of asymmetric hydrophosphorylation of simple styrenes, but also deepen our understanding of noncovalent interactions in ligand design.

Identifiers

PMID40593478
PMCPMC12216471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.